If a cancer drug successfully passes all phases of clinical trials, the sponsor can submit a New Drug Application (NDA) to the FDA. The NDA includes all data from the clinical trials and other relevant information. If the FDA determines that the drug is safe and effective for its intended use, it will approve the drug for marketing. Post-marketing surveillance continues to monitor the drug’s performance in the general population.
